Bevacizumab exacerbates sinusoidal obstruction syndrome (SOS) in the animal model and increases MMP 9 production

BACKGROUND: Thanks to modern multimodal treatment the ouctome of patients with colorectal cancer has experienced significant improvements. As a downside, agent specific side effects have been observed such as sinusoidal obstruction syndrome (SOS) after oxaliplatin chemotherapy (OX). Bevazicumab targ...

Descripción completa

Detalles Bibliográficos
Autores principales: Jafari, Azin, Matthaei, Hanno, Wehner, Sven, Tonguc, Tolga, Kalff, Jörg C., Manekeller, Steffen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955173/
https://www.ncbi.nlm.nih.gov/pubmed/29774103
http://dx.doi.org/10.18632/oncotarget.25021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955173/
https://www.ncbi.nlm.nih.gov/pubmed/29774103
http://dx.doi.org/10.18632/oncotarget.25021

Ejemplares similares